Last reviewed · How we verify
Juan A. Arnaiz — Portfolio Competitive Intelligence Brief
12 marketed
0 filed
7 Phase 3
0 Phase 2
1 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Darunavir/r | Darunavir/r | marketed | HIV protease inhibitor | HIV protease | Infectious Disease | |
| HAART + Immunotherapy | HAART + Immunotherapy | marketed | Combination antiretroviral + immunotherapy | Immunology, Infectious Disease, Oncology | ||
| Antiretroviral therapy alone | Antiretroviral therapy alone | marketed | ||||
| Antiretroviral therapy plus Interleukin-2 | Antiretroviral therapy plus Interleukin-2 | marketed | Combination immunotherapy and antiviral | HIV reverse transcriptase, protease, integrase (ART component); IL-2 receptor (IL-2 component) | Immunology / Infectious Disease | |
| Fosfomycin and imipenem | Fosfomycin and imipenem | marketed | Beta-lactam antibiotic combination | Bacterial cell wall synthesis (MurA enzyme and penicillin-binding proteins) | Infectious Disease | |
| Switch ritonavir-boosted PI | Switch ritonavir-boosted PI | marketed | Protease inhibitor (boosted) | HIV protease | Infectious Disease | |
| Tenofovir + emtricitabine + lopinavir/ritonavir | Tenofovir + emtricitabine + lopinavir/ritonavir | marketed | Antiretroviral combination (NRTI + protease inhibitor) | HIV reverse transcriptase, HIV protease | Infectious Disease / Virology | |
| Atazanavir / Ritonavir + Tenofovir / Emtricitabine | Atazanavir / Ritonavir + Tenofovir / Emtricitabine | marketed | Antiretroviral combination (protease inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors) | HIV protease, HIV reverse transcriptase | Infectious Disease / Virology | |
| elvitegravir/cobicistat/emtricitabine/tenofovir | elvitegravir/cobicistat/emtricitabine/tenofovir | marketed | Antiretroviral combination (INSTI + pharmacokinetic booster + NRTIs) | HIV integrase, CYP3A4, HIV reverse transcriptase | Infectious Disease / Virology | |
| Darunavir / Ritonavir + Tenofovir / Emtricitabine | Darunavir / Ritonavir + Tenofovir / Emtricitabine | marketed | Antiretroviral combination (protease inhibitor + nucleoside reverse transcriptase inhibitors) | HIV protease, HIV reverse transcriptase | Infectious Disease / Virology | |
| Continue Ritonavir-boosted PI+Rosuvastatin | Continue Ritonavir-boosted PI+Rosuvastatin | marketed | Antiretroviral combination (protease inhibitor + statin) | HIV protease (PI component); HMG-CoA reductase (rosuvastatin component) | Infectious Disease / Cardiovascular | |
| tenofovir + emtricitabine + atazanavir-ritonavir | tenofovir + emtricitabine + atazanavir-ritonavir | marketed | Antiretroviral combination (NRTI + PI/r) | HIV reverse transcriptase, HIV protease | Infectious Disease / Virology |
Therapeutic area mix
- Infectious Disease / Virology · 11
- Infectious Disease · 4
- Immunology / Infectious Disease · 1
- Immunology, Infectious Disease, Oncology · 1
- Infectious Disease / Cardiovascular · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- ViiV Healthcare · 3 shared drug classes
- Community Research Initiative of New England · 3 shared drug classes
- Drugs for Neglected Diseases · 2 shared drug classes
- University of Cologne · 2 shared drug classes
- Bristol-Myers Squibb · 2 shared drug classes
- Baqiyatallah Medical Sciences University · 1 shared drug class
- Central Institute of Epidemiology, Moscow, Russia · 1 shared drug class
- DualityBio Inc. · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Juan A. Arnaiz:
- Juan A. Arnaiz pipeline updates — RSS
- Juan A. Arnaiz pipeline updates — Atom
- Juan A. Arnaiz pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Juan A. Arnaiz — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/juan-a-arnaiz. Accessed 2026-05-16.